These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16955119)

  • 1. Immune globulin IV therapy: optimizing care of patients in the oncology setting.
    Shelton BK; Griffin JM; Goldman FD
    Oncol Nurs Forum; 2006 Sep; 33(5):911-21. PubMed ID: 16955119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.
    Daoud YJ; Amin KG
    Int Immunopharmacol; 2006 Apr; 6(4):600-6. PubMed ID: 16504922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events associated with intravenous immunoglobulin therapy.
    Hamrock DJ
    Int Immunopharmacol; 2006 Apr; 6(4):535-42. PubMed ID: 16504916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products.
    Gürcan HM; Keskin DB; Ahmed AR
    Autoimmun Rev; 2010 Jun; 9(8):553-9. PubMed ID: 20346419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The nurse's role in administration of intravenous immunoglobulin therapy.
    Kirmse J
    Home Healthc Nurse; 2009 Feb; 27(2):104-11; quiz 112-3. PubMed ID: 19212223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Home infusion of intravenous immunoglobulin.
    Banks MA
    J Intraven Nurs; 1994; 17(6):299-310. PubMed ID: 7853114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nurse's role in diarrhea management.
    Hogan CM
    Oncol Nurs Forum; 1998 Jun; 25(5):879-86. PubMed ID: 9644704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The patient: Emerging clinical applications of intravenous immunoglobulin.
    Harvey RD
    Pharmacotherapy; 2005 Nov; 25(11 Pt 2):85S-93S. PubMed ID: 16229679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of risk-management approaches to protect patients with cancer-related pain and their healthcare providers.
    Miaskowski C
    Oncol Nurs Forum; 2008 Nov; 35 Suppl():20-4. PubMed ID: 18980936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences between IGIV products: impact on clinical outcome.
    Gelfand EW
    Int Immunopharmacol; 2006 Apr; 6(4):592-9. PubMed ID: 16504921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura.
    Bussel JB; Hanna K;
    Am J Hematol; 2007 Mar; 82(3):192-8. PubMed ID: 17109385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal insufficiency and failure associated with immune globulin intravenous therapy--United States, 1985-1998.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1999 Jun; 48(24):518-21. PubMed ID: 10401909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Massage therapy as a supportive care intervention for children with cancer.
    Hughes D; Ladas E; Rooney D; Kelly K
    Oncol Nurs Forum; 2008 May; 35(3):431-42. PubMed ID: 18467292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous infusion chemotherapy in the ambulatory setting: the nurse's role in patient selection and education.
    Reville B; Almadrones L
    Oncol Nurs Forum; 1989; 16(4):529-35. PubMed ID: 2755860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Giving intravenous immunoglobulin.
    Scherf R; White-Reid K
    RN; 2008 Jan; 71(1):29-34; quiz 35. PubMed ID: 18271361
    [No Abstract]   [Full Text] [Related]  

  • 16. Availability of immune globulin intravenous for treatment of immune deficient patients--United States, 1997-1998.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1999 Mar; 48(8):159-62. PubMed ID: 10079062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process.
    Teschner W; Butterweck HA; Auer W; Muchitsch EM; Weber A; Liu SL; Wah PS; Schwarz HP
    Vox Sang; 2007 Jan; 92(1):42-55. PubMed ID: 17181590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pocketbook: Pharmacoeconomic issues related to intravenous immunoglobulin therapy.
    Mahadevia PJ
    Pharmacotherapy; 2005 Nov; 25(11 Pt 2):94S-100S. PubMed ID: 16229680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate therapy for metastatic bone disease: the pivotal role of nurses in patient education.
    Fitch MI; Maxwell C
    Oncol Nurs Forum; 2008 Jul; 35(4):709-13. PubMed ID: 18591175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing practice guidelines for the administration of intravenous immunoglobulin.
    Murphy E; Martin S; Patterson JV
    J Infus Nurs; 2005; 28(4):265-72. PubMed ID: 16106210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.